Systematic review: Patient-reported outcomes in chronic hepatitis C - The impact of liver disease and new treatment regimens

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 6, 2015, Pages 497-520

  Younossi, Z ^a   Henry, L ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR; INTERFERON; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ABSENTEEISM; ANEMIA; ANXIETY; ARTICLE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MEDICATION COMPLIANCE; MIXED INFECTION; NAUSEA; OUTCOME ASSESSMENT; PRODUCTIVITY; QUALITY OF LIFE; RASH; SELF REPORT; SYSTEMATIC REVIEW; DRUG COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84922855628     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13090     Document Type: Article

References (136)

1. Younossi ZM, Kanwal F, Saab S, et al,. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39: 518-31.
2. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S,. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530-7.
3. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
4. Manns MP, Cornberg M,. Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 2013; 13: 378-9.
5. Appleby J,. VA, California Panels Urge Costly Hepatitis C Drugs For Sickest Patients. April 17, 2014. Available at http://www.kaiserhealthnews.org/Stories/2014/April/17/hepatitis-c-sovaldi-panels-urge-approval.aspx (accessed 7 August 2014).
6. FDA Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf (accessed 29 July 2014).
7. Patel K, McHutchison JG,. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med 2004; 71 (Suppl. 3): S8-12.
8. Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok AS,. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004; 2: 425-31.
9. Tossing G,. Treating hepatitis C in HIV-HCV coinfected patients. Infection 2002; 30: 329-31.
10. Butt AA, Wagener M, Shakil AO, Ahmad J,. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12: 81-5.
11. Quelhas R, Lopes A,. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psychiatr Pract 2009; 15: 262-81.
12. Bacon BR, McHutchison JG,. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care 2005; 11 (10 Suppl): S296-306; quiz S307-11.
13. McCombs J, Matsuda T, Tonnu-Mihara I, et al,. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014; 174: 204-12.
14. Hassanein T, Cooksley G, Sulkowski M, et al,. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.
15. Rockstroh JK,. Summary from EASL 2013 for Hepatitis C-New HCV DAAs on Their Way Soon: What Do the Phase III Studies Tell Us? EASL 48th Annual Meeting. 24-28 April 2013, Amsterdam, The Netherlands.
16. Maasoumy B, Port K, Markova AA, et al,. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e55285.
17. Loria A, Doyle K, Weinstein AA, et al,. Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil 2014; 93: 470-6.
18. Younossi ZM, Stepanova M, Nader F, et al,. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59: 2161-9.
19. Younossi ZM, Stepanova M, Zeuzem S, et al,. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. J Hepatol 2014; 61: 228-34.
20. Younossi ZM, Stepanova M, Henry L, et al,. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol 2014; 60: 741-7.
21. Younossi Z, Stepanova M, Marcellin P, Afdhal N, Hunt SL,. Ledipasvir (LDV) and Sofosbuvir (SOF) Combination Improves Patient-Reported Outcomes (PRO) During Treatment Of Chronic Hepatitis C (CH-C) Patients: Results From The ION-1 Clinical Trial. Presented at International Liver Congress, London, England 2014
22. Younossi Z, Stepanova M, Marcellin P, Afdhal N, Hunt SL,. Substantial Improvement of Health-Related Quality of Life and Patient-Reported Outcomes in Chronic Hepatitis C (CH-C) Patients Treated with Ledipasvir (LDV) and Sofosbuvir (SOF): Results from ION-1 and 2. Digestive Disease Week, Chicago, IL, 2014.
23. Younossi ZM, Stepanova M, Henry L, et al,. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 12: 1349-57.
24. Ware JE, Kosinski M,. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001; 10: 405-13; discussion 415-20.
25. Martin L, Younossi Z,. Health-related quality of life (HRQOL) in chronic liver disease. Dig Liver Dis 2005; 37: 819-20.
26. Webster K, Odom L, Peterman A, et al,. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999; 8: 604.
27. Reilly MC, Zbrozek AS, Dukes EM,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
28. van der Plas SM, Hansen BE, de Boer JB, et al,. Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. Qual Life Res 2007; 16: 375-88.
29. The health measurement research group. Health Related Quality of Life Tools. Available at: http://www.healthmeasurement.org/Measures.html (accessed 16 April 2014).
30. Quality Metrics. Hepatitis Quality of Life Questionnaire (HQLQv2). Available at: http://www.qualitymetric.com/WhatWeDo/DiseasespecificHealthSurveys/HepatitisQualityofLifeQuestionnaireHQLQv2/tabid/193/Default.aspx (accessed 15 April 2014).
31. Centers for Disease Control-Health Related Quality of Life. Available at: http://www.cdc.gov/HRQoL/concept.htm (accessed 15 April 2014).
32. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D,. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.
33. van der Plas SM, Hansen BE, de Boer JB, et al,. The liver disease symptom index 2.0; validation of a disease-specific questionnaire. Qual Life Res 2004; 13: 1469-81.
34. De Bruin A, Diederiks J, De Witte L, Stevens F, Philipsen H,. The development of a short generic version of the sickness impact profile. J Clin Epidemiol 1994; 47: 407-12.
35. Two R, Verjee-Lorenz A, Clayson D, Dalal M, Grotzinger K, Younossi ZM,. A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health 2010; 13: 128-31.
36. ®): concepts, measurement properties and applications. Health Qual Life Outcomes 2003; 1: 1-10.
37. Tolley K,. What are Health Utilities? Health Economics 2009. Available at: http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/Health-util.pdf (accessed 26 July 2014).
38. Hsu PC, Federico CA, Krajden M, et al,. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 149-57.
39. McGrath C, Rofail D, Gargon E, Abetz L,. Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer's disease. Health Qual Life Outcomes 2010; 8: 23.
40. Longworth L, Bryan S,. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003; 12: 1061-7.
41. Quality Metrics. SF-6D. Available at: https://www.qualitymetric.com/Portals/0/Uploads/Documents/Public/SF-6D.pdf (accessed 10 October 2014).
42. Brazier J, Roberts J, Deverill M,. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-92.
43. Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH,. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care. 2011; 17: 657-64.
44. Escorpizo R, Bombardier C, Boonen A, et al,. Worker productivity outcome measures in arthritis. J Rheumatol 2007; 34: 1372-80.
45. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM,. Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531-9.
46. Tang K, Boonen A, Verstappen SM, et al,. Worker productivity outcome measures: OMERACT filter evidence and agenda for future research. J Rheumatol 2014; 41: 165-76.
47. Anderson RT, Baran RW, Erickson P, Revicki DA, Dietz B, Gooch K,. Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Qual Life Res 2014; 23: 877-86.
48. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F,. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800 Review.
49. LaFleur J, Hoop R, Morgan T, et al,. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res Notes 2014; 7: 266.
50. Mravčík V, Strada L, Stolfa J, et al,. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence 2013; 7: 1067-75.
51. Pawlotsky JM,. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011; 140: 746-54.
52. Poordad F, McCone J Jr, Bacon BR, et al,. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1195-206.
53. Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM,. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci 2014; 59: 3043-52.
54. Ioannou GN, Beste LA, Green PK,. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014; 12: 1371-80.
55. Bruno R, Cariti G, Nasta P, et al,. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCVgenotype 2/3 co-infection in Italy. Liver Int 2014; 35: 120-9.
56. McHutchison JG, Manns M, Patel K, et al,.; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
57. Niederau C, Mauss S, Schober A, et al,. Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS ONE 2014; 9: e107592.
58. Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A,; Nocchiero Study Group. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig Liver Dis 2006; 38: 119-24.
59. Klein MB, Lee T, Brouillette MJ, et al,. Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. HIV Clin Trials 2014; 15: 161-75.
60. Boscarino JA, Lu M, Moorman AC, et al,. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the chronic hepatitis cohort study (CHeCS). Hepatology 2014; doi: 10.1002/hep.27422 [Epub ahead of print]
61. Raptopoulou M, Tsantoulas D, Vafiadi I, et al,. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat 2005; 12: 91-5.
62. Afendy A, Kallman JB, Stepanova M, et al,. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 2009; 30: 469-76.
63. McHutchison JG, Ware JE Jr, Bayliss MS, et al,.; Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-7.
64. Ho SB1, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E,. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol 2008; 103: 1810-23.
65. Sublette VA, Hopwood M, George J, et al,. Instrumental support to facilitate hepatitis C treatment adherence: working around shortfalls in shared-care. Psychol Health Med 2014; 20: 1-12. [Epub ahead of print]
66. Les I, Doval E, Flavià M, et al,. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010; 22: 221-7.
67. Rodis JL, Kibbe P,. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs 2010; 33: 368-73.
68. Poordad F, Lawitz E, Kowdley KV, et al,. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
69. Bonner JE, Esserman DA, Golin CE, Evon DM,. Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol 2013; 20: 536-49.
70. Zacks S, Beavers K, Theodore D, et al,. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol 2006; 40: 220-4.
71. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR,. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004; 39: 999-1007.
72. Jerkeman A, Norkrans G, Lidman C, et al,. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities-completion rates and efficacy. Eur J Gastroenterol Hepatol 2014; 26: 523-31.
73. Grossel EJ, Ho SB, Aasch SM, Stepnowsky CJ, Laurent D, Gifford AL,. The hepatitis c self management program: sustainability of primary outcomes at 1 year. Health Educ Behav 2013; 40: 730-40.
74. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J,. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
75. John-Baptiste AA, Tomlinson G, Hsu PC, et al,. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.
76. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J,. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
77. Rowan PJ,. Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV? World J Virol 2013; 2: 139-45.
78. Sims OT, Whalen CC, Nackerud LG, Bride BE,. Longitudinal effects of selective serotonin reuptake inhibitor therapy and cytokine-related depression on hepatitis C viral logs during antiviral therapy. J Clin Psychopharmacol 2014; 34: 80-4.
79. Schaefer M, Sarkar R, Knop V, et al,. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012; 157: 94-103.
80. North CS, Hong BA, Adewuyi SA, et al,. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013; 35: 122-8.
81. Kondo Y, Yoshida H, Tateishi R, et al,. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 197-203.
82. Sobhonslidsuk A, Silpakit C, Kongsakon R, Satitpornkul P, Sripetch C, Khanthavit A,. Factors influencing health-related quality of life in chronic liver disease. World J Gastroenterol 2006; 12: 7786-91.
83. Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS,. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006; 23: 1629-35.
84. Younossi ZM,. Chronic liver disease and health-related quality of life. Gastroenterology 2001; 120: 305-7.
85. Gutteling JJ, Duivenvoorden HJ, Busschbach JJ, de Man RA, Darlington AS,. Psychological determinants of health-related quality of life in patients with chronic liver disease. Psychosomatics 2010; 51: 157-65.
86. Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS,. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007; 65: 227-34.
87. Häuser W, Holtmann G, Grandt D,. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2004; 2: 157-63.
88. Yang SS, Kao JH,. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2014; 9: 9-20.
89. Dan AA, Kallman JB, Srivastava R, Younoszai Z, Kim A, Younossi ZM,. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 2008; 14: 321-6.
90. Dan AA, Crone C, Wise TN, et al,. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics 2007; 48: 223-9.
91. Younossi Z, Kallman J, Kincaid J,. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 806-16.
92. Strauss E, Porto-Ferreira FA, de Almeida-Neto C, Teixeira MC,. Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself. Clin Res Hepatol Gastroenterol 2014; 38: 40-5.
93. Brener L, Horwitz R, von Hippel C, Bryant J, Treloar C,. Discrimination by health care workers versus discrimination by others: countervailing forces on HCV treatment intentions. Psychol Health Med 2014; 20: 148-53.
94. Solà E1, Watson H, Graupera I, et al,. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol 2012; 57: 1199-206.
95. Escheik C, Gerber L, Rover L, Arsalla Z, Otgonsuren M, Younossi ZM,. Validation of CLDQ-HCV as a Health Related Quality of Life (HRQOL) Instrument for Patients with Chronic Hepatitis C (CH-C). Presented at Program No. P240. ACG 2012 Annual Scientific Meeting Abstracts. Las Vegas, NV: American College of Gastroenterology. Available at: http://www.eventscribe.com/2012/acg/ajaxcalls/postersinfo.asp?title=7565 (accessed 14 April 2014).
96. Loria A, Escheik C, Gerber NL, Younossi ZM,. Quality of life in cirrhosis. Curr Gastroenterol Rep 2012; 15: 301.
97. Sobhonslidsuk A, Silpakit C, Kongsakon R, Satitpornkul P, Sripetch C,. Chronic liver disease questionnaire: translation and validation in Thais. World J Gastroenterol 2004; 10: 1954-7.
98. Carbone M, Bufton S, Monaco A, Griffiths L, Jones DE, Neuberger JM,. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 2013; 59: 490-4.
99. Sanyal A, Younossi ZM, Bass NM, et al,. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011; 34: 853-61.
100. Company L, Zapater P, Perez-Mateo M, Jover R,. Extrapyramidal signs predict the development of overt hepatic encephalopathy in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 519-25.
101. Arguedas MR, DeLawrence TG, McGuire BM,. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 1622-6.
102. Moscucci F, Nardelli S, Pentassuglio I, et al,. Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients. Liver Int 2011; 31: 1505-10.
103. Wang JY, Zhang NP, Chi BR, et al,. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol 2013; 19: 4984-91.
104. Marchesini G, Bianchi G, Amodio P, et al,.; Italian Study Group for quality of life in cirrhosis. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-8.
105. Kanwal F, Gralnek IM, Hays RD, et al,. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol 2009; 7: 793-9.
106. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT,. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
107. Strader DB, Seeff LB,. A brief history of the treatment of viral hepatitis C. Clin Liv Dis 2012; 1: 6-11.
108. Franciscus A,. HCV Education & Support: A Brief History of Hepatitis CHCSP. Version 5.1. March 2010 www.hcvadvocate.org
109. Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA,. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Pharm 2014; 20: 533-40.
110. McGowan CE, Fried MW,. Barriers to hepatitis C treatment. Liver Int 2012; 32 (Suppl. 1): 151-6.
111. Stepanova M, Kanwal F, El-Serag H, Younossi ZM,. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53: 737-45.
112. Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Hunt SH,. All Oral Therapy with Sofosbuvir Plus Ribavirin for the Treatment of Chronic Hepatitis C in Patients Co-infected with HIV (PHOTON-1 and PHOTON 2): the Impact on Patient-Reported Outcomes. J Infect Dis 2015; pii: jiv005. [Epub ahead of print]
113. DiBonaventura Md, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W,. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011; 14: 253-61.
114. Su J, Brook RA, Kleinman NL, Corey-Lisle P,. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010; 52: 436-42.
115. Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH,. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011; 17: 657-64.
116. Manne V, Sassi K, Allen R, Saab S,. Hepatitis C and work impairment: a review of current literature. J Clin Gastroenterol 2014; 48: 595-9.
117. Perrillo R, Rothstein KD, Rubin R, et al,. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11: 157-65.
118. ElKhoury AC, Vietri J, Prajapati G,. The burden of untreated HCV virus infection: a US patients' perspective. Dig Dis Sci 2012; 57: 2995-3003.
119. Liu G, DiBonaventura M, Yuan Y, et al,. The burden of illness for patients with viral HCV: evidence from a National Survey in Japan. Value Health 2012; 15: S65-71.
120. daCosta DiBonaventure M, Yuan Y, Wagner JS, et al,. The burden of viral HCV in Europe: a propensity analysis of patient outcomes. Eur J Gastroenterol Hepatol 2012; 24: 869-77.
121. Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM,. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther 2014; 40: 676-85.
122. Bonkovsky HL, Snow KK, Malet PF, et al,.; HALT-C Trial Group. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46: 420-31.
123. -Jacobson IM, Gordon SC, Kowdley KV, et al,.; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
124. Afdhal N, Zeuzem S, Kwo P, et al,.; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1889-98.
125. Afdhal N, Reddy KR, Nelson DR, et al,.; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1483-93.
126. Zeuzem S, Dusheiko GM, Salupere R, et al,.; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370: 1993-2001.
127. Kowdley KV, Gordon SC, Reddy KR, et al,.; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
128. Dalgard O, Bjøro K, Ring-Larsen H, et al,.; North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
129. Press Release. Available at: http://www.prnewswire.com/news-releases/abbvie-completes-largest-phase-iii-program-of-an-all-oral-interferon-free-therapy-for-the-treatment-of-hepatitis-c-genotype-1-242911871.html (accessed 6 Oct 2014).
130. Nachega JB, Parienti J, Olalekan J, et al,. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 58: 1297-307; first published online January 22, 2014.
131. Kowdley KV, Lawitz E, Poordad F, et al,. Safety and Efficacy of Interferon-Free Regimens of ABT-450/r, ABT-267. ABT-333 ± Ribavirin in Patients with Chronic HCV GT1 Infection: Results From the Aviator Study. Poster presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, The Netherlands.
132. Baran RW, Xie W, Liu Y, Cohen DE, Gooch K,. Health Related Quality of Life (HRQoL), Health State, Function and Wellbeing of Chronic HCV Patients Treated with Interferon-Free, Oral DAA Regimens: Patient Reported Outcome (PRO) Results from the Aviator study. Poster presented at: 64th Annual Meeting of the American Association for the Study of Liver Disease: Nov 1-5 2013; Washington, DC. P 1113.
133. ™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C. Available at: http://www.jnj.com/news/all/OLYSIO-simeprevir-Receives-FDA-Approval-for-Combination-Treatment-of-Chronic-Hepatitis-C (accessed 15 October 2014).
134. Scott J, Rosa K, Fu M, et al,. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2014; 14: 465.
135. Jacobson IM, Dore GJ, Foster GR, et al,. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
136. Forns X, Lawitz E, Zeuzem S, et al,. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79. e3.